Skip to main content
Premium Trial:

Request an Annual Quote

Biocept, Cleared4 Partner to Provide COVID-19 Testing, Management Service

NEW YORK – Biocept said Wednesday that it has partnered with health validation firm Cleared4 to develop a system for tracking and managing COVID-19 testing requirements and test results for Biocept customers.

The new service uses Cleared4's health platform, allowing organizations that have contracted Biocept for COVID-19 testing to incorporate customized protocols and requirements for their individual situation. The platform will integrate results from Biocept's RT-PCR-based COVID-19 testing in real time, and administrators will be able to monitor the program and results for their organizations via a secure dashboard.

Financial terms of the deal were not disclosed.

Cleared4 describes its platform as a turnkey system that enables an individual's health status to be connected to any form of access control in real time, including venue apps or employer tools. It allows users to customize their own requirements for symptom checking, test results, and vaccination data to trigger access to a whole location or a specific zone within a location.

"As our customers strive to safely reopen or increase populations at campuses, businesses, healthcare facilities and other venues, there is an urgent need for a system to help streamline implementation of testing protocols and track COVID-19 testing results. Our goal is to help ease the administrative burden of complying with complex health requirements for our customers," Biocept CEO Michael Nall said in a statement.

Biocept's PCR-based COVID-19 testing launched last year as the pandemic expanded and has rapidly come to dwarf its core cancer liquid biopsy services. The company said it has received more than 400,000 samples for COVID-19 testing to date.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.